Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02957526 · ClinicalTrials.gov registry record · NA
Web-Base App To Improve Aromatase Inhibitor Adherence
A NA study of Breast Neoplasm Female, sponsored by University of Tennessee.
- Completed
- Registry status
- NA
- Development phase
- 44
- Enrollment target
- 2
- Study locations
NCT02957526: Completed NA study of Breast Neoplasm Female, sponsored by University of Tennessee.
NCT02957526 is a NA study of Breast Neoplasm Female that has completed, run by University of Tennessee. The registered enrollment target is 44 participants, below the 175-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (75% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02957526, a NA study of Breast Neoplasm Female, has completed, sponsored by University of Tennessee.
- COMPLETED
- Registry status
- NA
- Development phase
- 44 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of the initial prescription to an aromatase inhibitor to improve communication and management of treatment-related adverse symptoms among patients with hormone-receptor positive breast cancer.
Primary Outcome
The primary data analysis will adhere to the intention-to-treat principle and in the final analysis, the participants will be categorized according to their initial randomization. Investigators will measure differences in aromatase inhibitor adherence at end of the study between the two study arms using the four-item Morisky Medication Adherence Scale.
Conditions Studied
Interventions
- BEHAVIORAL Prompts to report symptoms via study app
- BEHAVIORAL Clinical Alerts
Study Locations (2)
Tennessee
- West Cancer Center, MIDTOWN, 1588 Union Ave. - Memphis
- West Cancer Center, EAST MEMPHIS, 7945 Wolf River Blvd - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2015-12 |
| Est. Completion | 2016-07 |
| Phase | NA |
What the finished NCT02957526 record still lists
NCT02957526 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 175-participant average among 8 other Breast Neoplasm Female trials with a reported enrollment target (75% lower).
The record links to 1 condition, with Breast Neoplasm Female appearing as the primary indexed condition, and to 2 interventions - of which Prompts to report symptoms via study app is the first listed.
NCT02957526 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT02957526 about?
NCT02957526 is a clinical study titled "Web-Base App To Improve Aromatase Inhibitor Adherence". The purpose of this study will be to test the use of a web-based mobile application (app) initiated at the time of the initial prescription to an aromatase inhibitor to improve communication and management of treatment-related adverse symptoms among patients with hormone-receptor positive breast can...
What is the current status of trial NCT02957526?
This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2015-12. Estimated completion is 2016-07.
What conditions does trial NCT02957526 study?
This clinical trial studies the following conditions: Breast Neoplasm Female.
What interventions are being tested in trial NCT02957526?
The interventions under investigation include: Prompts to report symptoms via study app (BEHAVIORAL), Clinical Alerts (BEHAVIORAL).
Who is sponsoring clinical trial NCT02957526?
This trial is sponsored by University of Tennessee, which has 96 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02957526 being conducted?
This trial has 2 study locations across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Neoplasm Female
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02957526's enrollment target sits among peer trials
44 6th of 8 higher than 3 of 8 other Breast Neoplasm Female trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Neoplasm Female trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
RECRUITING · NA
-
The FYI on MRI: A Multilevel Decision Support Intervention for Screening Breast MRI
RECRUITING · NA
-
Study on Physical Activity's Relationship With Cancer and Cognition
COMPLETED · NA
-
Mayo Designed Soft Tissue Ultrasound-Detectable Marker
COMPLETED · NA
-
THRIVE Breast Cancer App Study
COMPLETED · NA
-
Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia